Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) in Infants During Their First RSV Season

Core Viewpoint - Merck has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) regarding ENFLONSIA (clesrovimab) for the prevention of Respiratory Syncytial Virus (RSV) in infants during their first RSV season [1] Group 1 - The positive CHMP opinion is a significant step towards potential approval for ENFLONSIA in the European market [1] - ENFLONSIA is specifically aimed at preventing RSV, which is a major cause of respiratory illness in infants [1] - The approval could enhance Merck's portfolio in the pediatric infectious disease market [1]